Alvogen’s subsidiary in Asia, Lotus Pharmaceuticals announces new global partnerships to drive growth
27 April 2020
  • Partnership agreements will further diversify Lotus revenue base and create partnerships with leading global pharma companies.

Lotus Pharmaceutical Co., Ltd. (Taiwan TWSE ticker: 1795) Alvogen’s subsidiary in Asia, today announced that it has made 10 new strategic partnership agreements in 2020 with some of the world’s leading pharmaceutical companies. The regions covered by these partnerships include the European Union, Middle East and North Africa (MENA), South Africa, Israel, Canada, Brazil and Columbia.

Lotus will be responsible for the development, regulatory affairs and manufacturing of the products for its partners that include Lenalidomide, Sunitinib, Enzalutamide. Recent partnership agreements have also been made for products still under development coming from Lotus’ leading oncology portfolio.

“We are pleased to have been able to strike agreements with these leading pharmaceutical companies. In doing so, we are diversifying our revenue base outside the APAC region and positioning Lotus as a global leader in oncology medicines and complex generics. The partnerships will also benefit patients around the world, which now may have better access to high quality medicines. The series of agreements are the product of a hard-working B2B team which is driven by the pursuit of delivering profitable growth, which can be reinvested in R&D, high-quality manufacturing, services and partnerships.”

Petar Vazharov

Chief Executive Officer of Lotus

Media Enquiries:
Angela Luan, Investor Relations Director +886 2 2700 5908 investor@lotuspharm.com

About Lotus Founded in 1966, Lotus is a generic company headquartered in Taiwan with high-value generic products covering CNS, CVS, oncology, women health, and anti-obesity drugs in tablets & hard/softgel capsule for global markets. It became an Alvogen Company in 2014. The primary focus of Lotus is on addressing the fast-growing oncology market. By aligning the company’s internal development and manufacturing capabilities, Lotus aims to benefit patients, its employees and shareholders alike. The company boasts a best in class R&D and manufacturing platform across Taiwan and Korea. Further, Lotus can reach nearly every global market with its high value pipeline through the company’s direct markets, relationship with Alvogen’s commercial units spanning over 30 countries, and through alliances with top-tier pharma companies.